Rein Therapeutics Inc. (NASDAQ:RNTX) Receives Average Rating of "Hold" from Brokerages

Key Points

• Rein Therapeutics received an average "Hold" rating from four brokerages, with a mix of one sell, one hold, and two buy ratings. The average 12-month price target is $6.00.
• The stock has been weak recently, trading at $0.85 and near its 52-week low of $0.83, with a market cap of about $72.5 million.
• The company beat earnings expectations in its latest quarter, reporting -$0.19 EPS versus the expected -$0.49. Rein Therapeutics is a clinical-stage biotech focused on tumor-activated IL-12 therapies, with lead candidate RT-101 in early trials.

Shares of Rein Therapeutics Inc. (NASDAQ:RNTX - Get Free Report) have received an average recommendation of "Hold" from the four ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $6.00.

A number of analysts recently commented on RNTX shares. Wall Street Zen upgraded Rein Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 6th. Maxim Group assumed coverage on Rein Therapeutics in a research report on Monday. They set a "buy" rating and a $4.00 target price for the company. HC Wainwright lowered their target price on Rein Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Monday, June 1st. Finally, Weiss Ratings downgraded shares of Rein Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday.

Institutional Investors Weigh In On Rein Therapeutics

Several large investors have recently modified their holdings of RNTX. Sigma Planning Corp raised its position in Rein Therapeutics by 41.0% during the first quarter. Sigma Planning Corp now owns 348,677 shares of the company's stock valued at $453,000 after purchasing an additional 101,400 shares in the last quarter. Chicago Partners Investment Group LLC grew its position in Rein Therapeutics by 32.2% during the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company's stock worth $53,000 after acquiring an additional 10,000 shares during the last quarter. State Street Corp grew its position in Rein Therapeutics by 374.3% during the 4th quarter. State Street Corp now owns 75,904 shares of the company's stock worth $88,000 after acquiring an additional 59,900 shares during the last quarter. Voss Capital LP increased its stake in Rein Therapeutics by 59.2% in the 4th quarter. Voss Capital LP now owns 4,243,969 shares of the company's stock worth $4,923,000 after purchasing an additional 1,577,437 shares during the period. Finally, Gagnon Securities LLC increased its stake in Rein Therapeutics by 5.0% in the 4th quarter. Gagnon Securities LLC now owns 240,220 shares of the company's stock worth $279,000 after purchasing an additional 11,528 shares during the period. Hedge funds and other institutional investors own 90.89% of the company's stock.

Rein Therapeutics Price Performance

Shares of RNTX stock traded down $0.01 during trading hours on Monday, reaching $0.85. The company had a trading volume of 554,610 shares, compared to its average volume of 433,444. Rein Therapeutics has a 12 month low of $0.83 and a 12 month high of $2.18. The business has a fifty day simple moving average of $0.99 and a 200-day simple moving average of $1.20. The company has a market cap of $72.54 million, a price-to-earnings ratio of -0.45 and a beta of 1.35.

Rein Therapeutics (NASDAQ:RNTX - Get Free Report) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.30. On average, equities research analysts expect that Rein Therapeutics will post -0.53 earnings per share for the current year.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company's core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.